Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study

Introduction

Posttraumatic stress disorder (PTSD) is associated not only with substantial psychological burden but also with poorer physical health and a higher risk of inflammatory conditions. The paper notes that prior research has repeatedly linked PTSD with elevated circulating inflammatory markers such as C-reactive protein (CRP), tumour necrosis factor alpha (TNF-α), and interleukin-6 (IL-6), but evidence on how PTSD treatments affect inflammation has been limited and inconsistent. Although MDMA-assisted therapy has shown rapid and robust effects on PTSD symptoms in earlier clinical trials, no previous study had examined inflammatory biomarker outcomes within this treatment context. The authors also frame the work against a broader background of HPA-axis dysregulation, chronic stress biology, and the possibility that symptom improvement may be accompanied by changes in immune signalling. The aim of this exploratory study was to examine within-person changes in inflammatory biomarkers during an MDMA-assisted group therapy intervention for Veterans with PTSD, and to explore whether biomarker levels were associated with PTSD symptom severity before and after treatment. The biomarkers selected were IL-6, TNF-α, and CRP, based on their prior relevance in PTSD and inflammation research. The authors expected MDMA-assisted group therapy to have anti-inflammatory effects, given the association between PTSD and inflammation and the symptom reductions seen in earlier MDMA-assisted therapy trials. This was an embedded biomarker substudy within a single-arm, open-label, pilot trial. The authors present it as the first study they are aware of to assess inflammatory biomarkers in the context of MDMA-assisted therapy for PTSD, including in a group format.